1. Home
  2. HUMAW vs PPBI Comparison

HUMAW vs PPBI Comparison

Compare HUMAW & PPBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HUMAW
  • PPBI
  • Stock Information
  • Founded
  • HUMAW 2004
  • PPBI 1983
  • Country
  • HUMAW United States
  • PPBI United States
  • Employees
  • HUMAW 220
  • PPBI N/A
  • Industry
  • HUMAW Biotechnology: Pharmaceutical Preparations
  • PPBI Major Banks
  • Sector
  • HUMAW Health Care
  • PPBI Finance
  • Exchange
  • HUMAW Nasdaq
  • PPBI Nasdaq
  • Market Cap
  • HUMAW N/A
  • PPBI N/A
  • IPO Year
  • HUMAW N/A
  • PPBI 1997
  • Fundamental
  • Price
  • HUMAW $0.48
  • PPBI $22.36
  • Analyst Decision
  • HUMAW
  • PPBI Buy
  • Analyst Count
  • HUMAW 0
  • PPBI 4
  • Target Price
  • HUMAW N/A
  • PPBI $27.25
  • AVG Volume (30 Days)
  • HUMAW 14.2K
  • PPBI 996.3K
  • Earning Date
  • HUMAW 03-21-2025
  • PPBI 07-23-2025
  • Dividend Yield
  • HUMAW N/A
  • PPBI 5.89%
  • EPS Growth
  • HUMAW N/A
  • PPBI 984.39
  • EPS
  • HUMAW N/A
  • PPBI 1.53
  • Revenue
  • HUMAW N/A
  • PPBI $591,231,000.00
  • Revenue This Year
  • HUMAW N/A
  • PPBI N/A
  • Revenue Next Year
  • HUMAW N/A
  • PPBI $6.74
  • P/E Ratio
  • HUMAW N/A
  • PPBI $14.63
  • Revenue Growth
  • HUMAW N/A
  • PPBI 40.61
  • 52 Week Low
  • HUMAW $1.18
  • PPBI $18.06
  • 52 Week High
  • HUMAW $1.34
  • PPBI $30.28
  • Technical
  • Relative Strength Index (RSI)
  • HUMAW N/A
  • PPBI 57.10
  • Support Level
  • HUMAW N/A
  • PPBI $20.93
  • Resistance Level
  • HUMAW N/A
  • PPBI $23.30
  • Average True Range (ATR)
  • HUMAW 0.00
  • PPBI 0.53
  • MACD
  • HUMAW 0.00
  • PPBI 0.14
  • Stochastic Oscillator
  • HUMAW 0.00
  • PPBI 69.38

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: